GSK: Fast Track Expansion Into Oncology, HIV, and Selective M&A - A Long Trade with a Clear Plan
GSK is executing a clear playbook: grow vaccines and specialty franchises, accelerate oncology and HIV investments via pipeline and selective buys, and defend margins with commercial scale. The stock trades at a reasonable multiple for a major pharma and yields ~3.3%. We like a long exposure with disciplined risk management, targeting a move back t…